- Home
- MED vs CHRS Comparison
MED vs CHRS Comparison
Compare MED & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MED
- CHRS
- Stock Information
- Founded
- MED 1980
- CHRS 2010
- Country
- MED United States
- CHRS United States
- Employees
- MED N/A
- CHRS N/A
- Industry
- MED Packaged Foods
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MED Consumer Staples
- CHRS Health Care
- Exchange
- MED Nasdaq
- CHRS Nasdaq
- Market Cap
- MED 152.3M
- CHRS 84.2M
- IPO Year
- MED N/A
- CHRS 2014
- Fundamental
- Price
- MED $14.58
- CHRS $0.82
- Analyst Decision
- MED Hold
- CHRS Buy
- Analyst Count
- MED 1
- CHRS 3
- Target Price
- MED $16.50
- CHRS $4.68
- AVG Volume (30 Days)
- MED 279.2K
- CHRS 1.3M
- Earning Date
- MED 08-04-2025
- CHRS 08-07-2025
- Dividend Yield
- MED N/A
- CHRS N/A
- EPS Growth
- MED N/A
- CHRS N/A
- EPS
- MED N/A
- CHRS N/A
- Revenue
- MED $543,452,000.00
- CHRS $272,251,000.00
- Revenue This Year
- MED N/A
- CHRS N/A
- Revenue Next Year
- MED N/A
- CHRS $106.56
- P/E Ratio
- MED N/A
- CHRS $1.87
- Revenue Growth
- MED N/A
- CHRS 19.87
- 52 Week Low
- MED $11.57
- CHRS $0.66
- 52 Week High
- MED $22.66
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- MED 60.34
- CHRS 53.13
- Support Level
- MED $12.95
- CHRS $0.72
- Resistance Level
- MED $14.90
- CHRS $0.77
- Average True Range (ATR)
- MED 0.67
- CHRS 0.04
- MACD
- MED 0.12
- CHRS 0.01
- Stochastic Oscillator
- MED 84.95
- CHRS 91.62
About MED MEDIFAST INC
Medifast Inc is a old health and wellness company known for its habit-based and coach-guided lifestyle solution OPTAVIA, which provides people with a simple, yet comprehensive approach to address obesity and support a healthy life. OPTAVIA provides unparalleled coaching support along with community, tailored nutrition and healthy habits, and empowers people to master their weight loss journey through each stage of life. The company has access to GLP-1 medications where clinically appropriate. Medifast remains committed to its mission of offering Lifelong Transformation, Making a Healthy Lifestyle Second Nature.
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.